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Abstract. One of the most commonly used drugs in chemo-
therapy, 5‑fluorouracil (5‑FU) has been shown to be effective 
in only 10‑15% of patients with colon cancer. Thus, studies 
of the mechanisms affecting 5‑FU sensitivity in these patients 
are necessary. The tumor suppressor protein p53 is a transcrip-
tion factor that serves important roles in cell apoptosis by 
regulating the cell cycle. It has also been characterized as a key 
factor influencing drug sensitivity. Furthermore, accessible 
chromatin is a hallmark of active DNA regulatory elements 
and functions as a crucial epigenetic factor regulating cancer 
mechanisms. The present study assessed the genetic regulatory 
landscape in colon cancer by performing RNA sequencing and 
Assay for Transposase‑Accessible Chromatin sequencing, and 
investigated the effects of 5‑FU on chromatin accessibility and 
gene expression. Notably, while treatment with 5‑FU medi-
ated global increases in chromatin accessibility, chromatin 
organization in several genomic regions differed depending 
on the expression status of p53. Since the occupancy of p53 
does not overlap with accessible chromatin regions, the 
5‑FU‑mediated changes in chromatin accessibility were not 
regulated by direct binding of p53. In the p53‑expressing 
condition, the 5‑FU‑mediated accessible chromatin region 
was primarily associated with genes encoding cell death 
pathways. Additionally, 5‑FU was revealed to induce open 
chromatin conformation at regions containing binding motifs 
for AP‑1 family transcription factors, which may drive expres-
sion of apoptosis pathway genes. In conclusion, expression 
of p53 may confer 5‑FU sensitivity by regulating chromatin 
accessibility of distinct genes associated with cell apoptosis in 
a transcription‑independent manner.
Introduction
Colorectal cancer ranks as the second most deadly cancer 
among all cancer types, and colorectal cancers are commonly 
treated with 5‑fluorouracil (5‑FU), anticancer drug. 5‑FU is 
known to interfere with DNA synthesis in cancer cells by 
inhibiting thymidylate synthase, as a mechanism that inhibits 
cell proliferation and leads to cell death (1‑3). Although 5‑FU 
plays a central role in the treatment of colorectal cancer, it 
elicits any effect in only 10-15% of colorectal cancer patients, 
and approximately 40-50% of treatments are successful upon 
combination therapy with other antitumor drugs, including 
oxaliplatin, leucovorin, and others. Therefore, outlining the 
mechanisms underlying sensitivity to 5‑FU among colorectal 
cancer cells would be helpful.
Cancer research has shown p53 to be a tumor suppressor, 
and p53 dysfunction has been found to lead to the development 
of colorectal cancer. Moreover, p53 has been characterized a 
key factor influencing drug sensitivity: p53 overexpression has 
been shown to increase the effect of chemotherapy in patients 
with stage III colorectal cancer with mutant p53 (4‑6). The 
major biological function of p53 is to initiate cell apoptosis 
by regulating the cell cycle at the G1/S and the G2/M check 
points. Interestingly, p53 studies have indicated that active p53 
exhibits both transcriptional and non‑transcriptional activity 
and that both can affect apoptosis. Under various cell death 
conditions, the non‑transcriptional activity of p53 induces 
mitochondrial outer membrane permeabilization (MOMP), 
and this triggers the release of pro-apoptotic factors from the 
mitochondrial inter‑membrane space (7‑9).
Chromatin structure and organization influence the identity 
of cells by regulating cell‑specific signaling networks (10,11), 
and recently, various epigenetic studies have reported a link 
between alterations in chromatin structure and cancer progres-
sion (12‑15). Measurement of chromatin accessibility during 
prostate cancer progression revealed that chromatin relaxation 
increases the binding of oncogenic transcription factors, 
resulting in increased expression of tumor growth‑related 
genes (16,17). Another report showed that TGF‑β induces 
chromatin accessibility to cis‑regulatory elements of 
epithelial-to-mesenchymal transition-related genes, including 
CDH1, CDH2, and VIM. Additionally, research has shown 
that TGF‑β induced chromatin accessibility increases the 
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transcriptional activity of RUNX, AP‑1, and Etv4/5, and 
results in epithelial-to-mesenchymal transition in mammary 
gland epithelial cells (18). Altogether, these studies indicate 
that external stimuli can affect chromatin accessibility and 
that such effects are strongly related with stimulus‑mediated 
cellular phenotypes.
While it is known that p53 plays a key role in successful 
chemotherapy, the mechanisms of how p53 affects 5‑FU sensi-
tivity remain unknown. Rubbi and Milner (19) showed that 
ultraviolet radiation induces p53‑mediated global chromatin 
relaxation. However, the authors did not demonstrate the effects 
of global chromatin relaxation on DNA damage‑induced cell 
death (19). Therefore, in this study, we hypothesized that 
since 5‑FU is also a DNA‑damaging reagent, like ultraviolet 
radiation, TP53‑wild‑type (TP53‑WT) and TP53‑knockout 
(TP53‑KO) colorectal cancer cells would show differences 
in gene expression at chromatin accessible regions under 
5‑FU treatment and that such differences would affect 5‑FU 
sensitivity depending on p53 status. To prove our hypothesis, 
we performed Assay for Transposase‑Accessible Chromatin 
sequencing (ATAC‑seq) to assess chromatin accessibility 
and RNA sequencing (RNA‑seq) to measure associated gene 
expression in both TP53‑WT and TP53‑KO colorectal cancer 
cells exposed to 5‑FU treatment.
Materials and methods
Cell culture. The human colorectal carcinoma cell line 
HCT116 TP53‑WT and HCT116 TP53‑KO, initially 
described by Bunz et al (20), were obtained as a kind gift 
from Dr Jae‑Hoon Jeong (Korea Institute of Radiological 
and Medical Sciences, Korea). The genetic background of 
TP53‑WT and TP53‑KO were verified by performing geno-
typing using PCR primers (Table SI), which amplify a 220‑bp 
band for TP53 exon 2 and a 519‑bp band for CTCF exon 12 
as the control (Fig. S1). Target DNA for genotyping was 
amplified using Dr. Taq DNA Polymerase (Allforlab) with 
initial denaturation at 95˚C for 3 min, followed by 35 cycles 
of denaturation at 95˚C for 10 sec, annealing at 63˚C for 
30 sec, extension at 72˚C for 1 min, and a final elongation 
step at 72˚C for 5 min. Cells were cultured in Roswell Park 
Memorial Institute 1640 medium (Hyclone) supplemented 
with 10% fetal bovine serum (Hyclone) and 1% penicillin/
streptomycin (100 U/ml:100 µg/ml; Hyclone) and were grown 
at 37˚C, 5% CO2, and 98% humidity.
Cell viability assay. Cell viability was analyzed using 
CellTiter Glo (Promega, G7570) according to the 
manufacturer's instructions. Luminescence was measured 
using a microplate luminometer (Berthold Centro XS3 
LB 960) and MikroWin2000 software.
ChIPmentation library preparation. Chromatin immuno-
precipitation followed by sequencing (ChIP‑seq) assays were 
performed using p53 antibodies (Santa Cruz Biotechnology, 
Inc.; cat. no. sc‑126) as described previously (21) with minor 
modifications. ChIP‑seq libraries were prepared using a Nextera 
DNA Sample Prep kit (Illumina, Inc.) according to the manu-
facturer's instructions. Libraries were sequenced on an Illumina 
HiSeq 2500 system, generating 100 bp paired‑end reads.
RNA‑seq library preparation. Total RNA was isolated 
using Hybrid‑R Total RNA kits (GeneAll Biotechnology 
Co. Ltd.), and rRNAs were depleted by using the NEBNext 
rRNA Depletion kit (NEB; cat. no. E6350). RNA sequencing 
(RNA‑seq) libraries was prepared using NEBNext Ultra RNA 
library prep kits (NEB; cat. no. 7770) according to the manu-
facturer's instructions. Libraries were sequenced on an Illumina 
HiSeq 2500 system, generating 100 bp paired‑end reads.
ATAC‑seq library preparation. Assay for Transposase‑ 
Accessible Chromatin sequencing (ATAC‑seq) libraries were 
prepared as described previously (22) and sequenced on an 
Illumina HiSeq 2500 system, generating 100 bp paired‑end 
reads.
ChIP‑seq data processing. Raw reads were trimmed using 
trim galore with default parameters to remove low quality 
and adapter sequences. Trimmed reads were mapped to the 
human genome reference hg19 using BWA (23). The refer-
ence genome was downloaded from GENCODE V19. Reads 
with low mapping quality were filtered using SAMtools (24). 
MAPQ <30 were used to obtain uniquely mapped reads. 
Duplicated reads were filtered using Picard (Picard version 
2.23.9; https://broadinstitute.github.io/picard). Reads mapped 
to mitochondrial chromosomes were filtered. Peaks were 
called using MACS2 (25) with input DNA as a control.
ATAC‑seq data processing. Raw reads were trimmed using 
trim galore with the same default parameters as in ChIP‑seq 
analysis. Trimmed reads were mapped to the hg19 reference 
genome using BWA (23). Fragments below 2,000 bp were 
allowed. Reads with low mapping quality were filtered using 
SAMtools (24). Duplicated reads and mitochondrial chromo-
somes were filtered as described above. Since Tn5 transposase 
binds as a dimer and inserts two adaptors separated by 9 bp, all 
aligned reads were shifted by +4 bp on the positive strand and 
‑5 bp on the negative strand using the deepTools (26) function 
alignmentSieve. To obtain nucleosome free regions, frag-
ments over 140 bp in length were filtered out. ATAC‑seq peak 
calling was performed using MACS2 (25). ATAC‑seq peaks 
across samples were merged using mergePeaks, and differen-
tial peaks were called using Homer getDifferentialPeaks.pl 
(Homer version 4.11; http://homer.ucsd.edu). Overlapping of 
open chromatin regions with enrichment of p53 was analyzed 
using bedtools (27) intersect: Overlap of at least 1‑bp intervals 
was counted. Homer annotatePeaks.pl was used to annotate 
differential ATAC‑seq peaks to their nearest genes. Homer 
findMotifsGenome.pl. was used to identify motifs enriched at 
open chromatin regions. ATAC‑seq and ChIP‑seq data were 
visualized using the Integrative Genomics Viewer (28).
RNA‑seq data processing. Raw reads were trimmed using 
trim galore. For transcript abundance quantification analysis, 
STAR (29) was used to map the reads to the human genome. 
RSEM (30) was used to quantify transcripts. Differentially 
expressed genes between groups were calculated using DESeq2 
R package (31). Genes with low read counts were filtered out 
before differential analysis. DESeq2 provides a statistical 
analysis method and assessment of differential expression 
using a model based on negative binomial distribution. Gene 
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ontology and pathway enrichment analyses were performed 
using the Enrichr online tool (32,33).
Statistics. All experimental values are presented as 
mean ± SD. Cell viability assays were performed in triplicate, 
and RNA‑seq and ATAC‑seq experiments were performed in 
duplicate. Most of statistical significance was calculated by 
two‑way analysis of variance, in which P<0.05 was considered 
statistically significant (GraphPad Prism 7 software; GraphPad 
Software, Inc.). Post hoc multiple comparisons were followed 
by Bonferroni correction. Two groups were compared using 
unpaired Student's t‑test, in which P<0.001 was considered 
statistically significant (R version 4.0.3; The R Foundation).
Results
Chromatin accessibility changes in response to 5‑FU 
depending on p53 status. Responding to drug stimulation, 
p53 has been shown to increase drug sensitivity in various 
cancer cells (34,35). In order to investigate the effects of p53 
on responses to 5‑FU among colorectal cancer cells (HCT116 
cells), we first treated TP53‑WT and TP53‑KO HCT116 cells 
with 5‑FU and then measured mRNA expression levels of 
p53 using RNA‑seq analysis. As expected, we noted that 
p53 expression increased under 5‑FU treatment at 24 h in 
TP53‑WT cells, but not TP53‑KO cells (Fig. 1A). Next, we 
performed cell viability assay and found that the presence 
of p53 conferred sensitivity to 5‑FU among HCT116 cells 
(Fig. 1B), clearly confirming the role of p53 in 5‑FU sensitivity 
in HCT116 cells.
Physical DNA accessibility is important in establishing 
and maintaining cellular identity through the regulation of 
the expression of various genes (36,37). Moreover, recent 
research has shown that drug‑mediated cellular replication 
stress induces chromatin remodeling and that such modifica-
tion is highly associated with drug responses in cells (38,39). 
To ascertain the effects of 5‑FU on chromatin accessibility, 
we performed ATAC‑seq before and after 5‑FU treatment, and 
found that global chromatin accessibility increased around 
3‑fold under 5‑FU treatment for 24 h in both TP53‑WT and 
TP53‑KO cells (Fig. 1C). Next, we analyzed regions showing 
differences in chromatin accessibility between TP53‑WT and 
TP53‑KO cells after 5‑FU treatment to evaluate the role of p53 
in 5‑FU‑mediated chromatin remodeling. When we merged 
and compared all ATAC‑seq peaks called from 5‑FU‑treated 
TP53‑WT and TP53‑KO cells, we found that chromatin 
accessibility was equal at 5152 regions in the cells under 
5‑FU treatment regardless of the presence of TP53 (Fig. 1D). 
Respectively, however, 5‑FU elicited higher chromatin acces-
sibility at 9,131 regions in TP53‑WT cells and at 9,900 regions 
in TP‑53‑KO cells (Fig. 1D). These data indicated that the 
expression status of p53 influences chromatin accessibility in 
response to 5‑FU.
It is well known that p53 functions as a transcription 
factor that binds to specific DNA sequences to trans‑activate 
a number of genes (40,41). To determine whether p53 impacts 
5‑FU‑mediated changes in chromatin accessibility by 
directly binding to regulatory regions of DNA, we performed 
chromatin immunoprecipitation followed by sequencing 
(ChIP‑seq) to analyze the distribution of binding sites for p53 
in TP53‑WT cells. Consistent with a previous report (42), most 
TP53 binding regions were located in inaccessible chromatin 
regions, and only 1.4% of 5‑FU‑induced accessible regions 
overlapped with TP53 binding sites (Fig. 1E). These results 
demonstrated that p53 influences 5‑FU‑mediated changes 
in chromatin accessibility in a transcription‑independent 
manner.
Changes in chromatin accessibility are associated with 
distinct gene expression profiles in response to 5‑FU. Next, 
we explored genome‑wide changes in gene expression profiles 
following 5‑FU treatment by performing RNA‑seq. In response 
to 5‑FU treatment, a larger number of differentially expressed 
genes (DEGs, fold change >2, P‑value <0.05) in TP53‑WT 
cells than in TP53‑KO cells (1693 genes in TP53‑WT versus 
583 genes in TP53‑KO) (Fig. 2A). Interestingly, 772 and 281 
DEGs from TP53‑WT and TP53‑KO cells, respectively, were 
directly associated with 5‑FU‑induced changes in chromatin 
accessibility (Fig. 2A). Moreover, expression of 551 and 150 
genes were significantly increased following 5‑FU treatment 
in TP53‑WT and TP53‑KO cells, respectively (Fig. 2B). 
Gene ontology analysis for 5‑FU‑mediated upregulated 
genes harboring differentially accessible regions (DARs) 
in TP53‑WT cells revealed significant enrichment of genes 
known to be associated with p53 pathways, apoptosis, and 
genotoxicity (Fig. 2C), while those in TP53‑KO cells showed 
enrichment of genes associated with cancer progression, 
including senescence and autophagy, circadian rhythm-related 
genes, melatonin metabolism, and PI3K‑AKT‑mTOR signaling 
(Fig. 2D). Moreover, we found that 135 genes were overlapped 
among the genes whose expressions and chromatin accessibili-
ties were changed after 5‑FU treatment in both TP53‑WT and 
TP53‑KO cells. Gene ontology analysis of these overlapped 
genes revealed significant enrichment of genes associated 
with transcription regulation, cell differentiation regulation 
and apoptosis (Fig. S2). These results indicated that changes 
in chromatin accessibility in response to 5‑FU elicit distinct 
gene expression profiles in colorectal cancer cells depending 
on p53 status.
Specific chromatin accessible regions in TP53‑WT cells are 
highly associated with expression of cell death‑related genes. 
Among the regions showing higher 5‑FU‑mediated chro-
matin accessibility in TP53‑WT cells, compared to TP53‑KO 
cells (Figs. 1D and 3A), we selected DARs that exhibited a 
greater than two‑fold increase in TP53‑WT cells, with an 
adjusted P‑value of less than 0.05. The annotation of these 
TP53‑WT‑specific DARs to their nearest genes allowed us 
to identify 95 genes with significantly higher expression in 
TP53‑WT cells than TP53‑KO cells (Fig. 3B; Table SII). Gene 
ontology analysis demonstrated that these TP53‑WT‑specific 
upregulated genes were significantly enriched in cell death 
pathways (Table I). As a representative example, Fig. 3C 
shows that chromatin accessibility in the promoter regions of 
two tumor suppressor genes, SEMA3B and PHLDA3, as well 
as their mRNA levels, significantly increased in response to 
5‑FU treatment in TP53‑WT cells only. De novo transcrip-
tion factor binding motif analysis revealed that AP‑1 complex 
motifs were enriched at the TP53‑WT specific chromatin 
accessible regions (P=1x10‑31) (Fig. 3D). AP‑1 complex is a well 
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characterized transcription factor family known to be activated 
in response to various cellular stress signals, and research has 
shown that it regulates various genes related with proliferation, 
immune response, and cell death (43). One of the AP‑1 family 
transcription factors in particular, c‑Jun, has been found to 
inhibit cell proliferation and to induce apoptosis in response to 
genotoxic stress by increasing caspase activity (44‑46). These 
results suggest that, unlike in TP53‑KO cells, 5‑FU elicits 
Figure 1. Distinct changes in chromatin accessibility in response to 5‑FU depending on p53 status (A) TP53 mRNA expression levels were measured by 
RNA‑seq for TP53‑WT or ‑KO cells treated with 300 µM 5‑FU for the indicated time points (n=2 per group). (B) The viability of TP53‑WT and TP53‑KO cells 
measured 72 h after treatment of various concentration of 5‑FU (n=6 per group). (C) Histogram showing the average tag density of ATAC‑seq peaks called for 
TP53‑WT and TP53‑KO cells before and after treatment with 5‑FU for 24 h. (D) Heatmap showing differentially accessible chromatin regions in TP53‑WT 
and TP53‑KO cells before and after treatment with 5‑FU for 24 h. (E) Venn diagram showing the overlap of TP53 ChIP‑seq peaks and ATAC‑seq peaks 
in TP53‑WT cells treated with 5‑FU for 24 h (left), and a genomic snapshot depicting representative DARs (right). The data are presented as a mean ± SD. 
*P<0.05; **P<0.01; ***P< 0.001. DARs, differentially accessible regions; TP53‑WT, TP53‑wild‑type; TP53‑KO, TP53‑knockout.
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increases in chromatin accessibility at specific regions in 
TP53‑WT cells that promote the binding of AP‑1 transcription 
factor to genes related to cell death, which may contribute to 
the higher sensitivity of TP53‑WT cells to 5‑FU.
Discussion
Modification of the structure of chromatin can affect the 
expression of various genes, and it results in changing 
Figure 2. Differential changes in chromatin accessibility depending on p53 status are associate with distinct gene expression profiles in response to 5‑FU. 
(A) Differentially expressed genes (DEGs) that exhibited greater than two‑fold changes with an adjusted P‑value of less than 0.05 are denoted in TP53‑WT 
and TP53‑KO cells based on the association with 5‑FU‑induced chromatin accessibility. (B) Volcano plot showing DEGs associated with 5‑FU‑induced DARs 
in TP53‑WT (left) and TP53‑KO (right) cells. (C) and (D) Pathway enrichment analysis for the genes that showed both higher mRNA expression and greater 
chromatin accessibility upon 5‑FU treatment for 24 h in TP53‑WT cells (C) or TP53‑KO cells (D). TP53‑WT, TP53‑wild‑type; TP53‑KO, TP53‑knockout.
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molecular signaling networks influencing cellular phenotypes. 
According to the research about the chromatin accessibility 
and architecture, extracellular stimulation remodels chromatin 
structure, and it results in modification of cellular signaling 
networks toward unique cellular phenotypes (18,47). In this 
study, we found through RNA‑ and ATAC‑seq that 5‑FU 
increases chromatin accessibility in colorectal cancer cells 
(HCT116 cells) and that the regions of increased chromatin 
accessibility induced by 5‑FU differed depending on p53 
status: In cells expressing p53, 5‑FU elicited increased 
chromatin accessibility in genes important to p53 pathways, 
apoptosis, and genotoxicity, whereas in cells not expressing 
p53, 5‑FU elicited increased chromatin accessibility in genes 
important to cancer progression.
ATAC‑seq is one of the best experimental techniques 
with which to measure chromatin accessibility, and it allows 
researchers to predict main transcription factors in cis-regulatory 
regions. In this study, we used ATAC‑seq to prove our hypoth-
esis that the sensitivity among colorectal cancer cells to 
5‑FU may be due to chromatin accessibility and p53 status. 
Figure 3. Distinct 5‑FU‑induced gene expression is associated with higher chromatin accessibility in TP53‑WT cells than TP53‑KO cells. (A) Violin plot 
showing 9,131 DARs with higher 5‑FU‑induced chromatin accessibility in TP53‑WT cells, compared to TP53‑KO cells (n=2 per group, ***P<0.001). (B) Volcano 
plot showing DEGs associated with 5‑FU‑induced DARs that exhibited a greater than two‑fold increase in TP53‑WT cells, with an adjusted P‑value of less 
than 0.05. The number of genes that exhibited greater than two‑fold increases in TP53‑WT (blue) and TP53‑KO (red) cells with a P‑value of less than 0.05 
are indicated. (C) Genomic snapshot of the SEMA3B (upper left) and PHLDA3 (lower left) genes showing the densities of ATAC‑seq reads in TP53‑WT and 
TP53‑KO cells before and after 5‑FU treatment for 24 h. Bar graph shows the mRNA expression levels of SEMA3B (upper right) and PHLDA3 (lower right) 
genes measured by RNA‑seq from TP53‑WT and TP53‑KO cells before and after 5‑FU treatment for 24 h (n=2 per group, *P<0.05; **P<0.01). (D) Enriched 
de novo motif analysis for the DARs that showed both higher mRNA expression and greater chromatin accessibility in TP53‑WT cells, compared to TP53‑KO 
cells, after 5‑FU treatment for 24 h. DARs, differentially accessible regions; TP53‑WT, TP53‑wild‑type; TP53‑KO, TP53‑knockout.
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ATAC‑seq clearly showed that 5‑FU increased chromatin 
accessibility in HCT116 cells (Fig. 1C and D). Noteworthy, 
5‑FU induced chromatin accessibility differed depending on 
p53 status in HCT116 cells (Fig. 1D). To identify p53 activi-
ties related with 5‑FU induced chromatin accessibility, we 
compared p53 ChIP‑seq and ATAC‑seq results under 5‑FU 
treatment in TP53‑WT cells. From the integration analysis, we 
found that the difference in chromatin accessibility was not 
the direct effect of p53 binding: 96% of p53 binding regions 
were located in chromatin inaccessible regions (Fig. 1E). Thus, 
we deemed that the effects of p53 on 5‑FU‑induced chromatin 
accessibility in TP53‑WT cells are related with non‑transcrip-
tional activities. Studies of p53 in relation to drug sensitivity 
have primarily focused on correlations between signaling 
networks and p53 status, such as genetic mutation and gene 
silencing, and most have focused solely on the transcriptional 
activities of p53 (34,48,49). Nonetheless, a few studies have 
recently described the effects of p53 non‑transcriptional 
activity on apoptosis. Although these studies only reported on 
MOMP (7‑9), their results, together with ours, indicate that p53 
may carry out several non‑transcriptional functions that await 
discovery. Given the high incidence of TP53 mutation in many 
different types of cancer, it would be interesting to explore 
the role of p53 in drug sensitivity and chromatin structure in 
diverse cancer cells, which is beyond the scope of the current 
study but remains to be our next project to pursue.
In motif analysis of regions showing increased chromatin 
accessibility upon treatment with 5‑FU in TP53‑WT cells, we 
detected the AP‑1 complex binding motif (Fig. 3D). Various 
contradictory functions have been reported for AP‑1 complex: It 
generally induces cell proliferation (50) and differentiation (51); 
however, one study has indicated that it also shows an apoptotic 
function (45). Of note, the contradictory functions of AP‑1, 
especially c‑JUN, appear to depend on the cellular context 
and extracellular stimuli (52). Although the function of AP‑1 
complex in relation to apoptotic signaling is still controversial 
and unclear, we presume that, through non‑transcriptional 
activity, p53 increases the accessibility of AP‑1 binding regions 
in response to treatment with 5‑FU in TP53‑WT cells, resulting 
in activation of apoptotic signaling pathways, thereby conferring 
5‑FU sensitivity. Unfortunately, however, since motif analysis 
is only useful in predicting possible binding proteins based on 
genomic sequences, we are unable to confirm the direct effects 
of AP‑1 complex on 5‑FU sensitivity based on these results 
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